Gianantonio Rosti

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio et al. · The Lancet Oncology · 2011 · 513 citations

Life Sciences, Hematology, Pharmacotherapy +7

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

Joerg Hasford, Michele Baccarani, Verena Hoffmann et al. · Blood · 2011 · 497 citations · Full text

Life Sciences, Biostatistics, Oncology +13

The effects of imatinib on pregnancy outcome

Seonaid Pye, Jörge E. Cortes, Patricia Ault et al. · Blood · 2008 · 392 citations

Medicine, Obstetrics, Pharmacotherapy +8

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Giovanni Martinelli, Gianantonio Rosti et al. · Journal of Clinical Oncology · 2005 · 372 citations · Full text

Medicine, Hematology, Pharmacology +14